Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
The requirement of bowel surgery is dramatically reduced by up to 60% in patients who develop Crohn's disease if they receive prolonged treatment with drugs called thiopurines, says a new study.
Crohn's affects more than quarter-of-a-million people in the UK leading to an inflamed intestine.
Researchers from St George's, University of London, St George's Hospital, London and Imperial College, London, monitored more than 5,000 patients in the UK living with Crohn's disease for more than 20 years and looked at the effect of thiopurine drugs that suppress inflammation in the gut.
Gastroenterologist Dr Richard Pollok, an honorary senior lecturer at St George's, University of London, said "Our discovery is timely since new guidelines from the USA have played down the benefits of these drugs in favour of newer agents.
"A year of treatment with the newer 'biologics', which are administered by injection, cost about £10,000 more compared to thiopurines.
"We try to avoid surgery but some patients face multiple procedures because the disease can flare up again particularly where the intestine has been rejoined.
"The fact that thiopurines can cut the need for surgical intervention and remain affordable is good news for patients and the NHS."
They found patients taking thiopurines, such as Azathioprine, for more than 12 months had a 60% reduction within the first 5 years of diagnosis.
Thiopurines have been used in the treatment of inflammatory bowel conditions like Crohn's disease since the 1970s but their long-term benefits have just come to light.
There has been a major increase in the number of patients who receive these drugs in the past decade and rates of surgery in patients with this condition have dropped, partly as a result of these and other treatments.
But up to a quarter of patients still go on to have their first corrective surgery to remove the worst affected areas within 5 years of being diagnosed.
The study, published in the American Journal of Gastroenterology, was funded by the National Institute for Health Research.
The Impact of Timing and Duration of Thiopurine Treatment on First Intestinal Resection in Crohn ’ s Disease: National UK Population-Based Study 1989 - 2010 , Authors: Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, Majeed A, Pollok R.C., The American Journal of Gastroenterology (Jan 2014) doi: 10.1038/ajg.2013.462
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Crohn's / IBD category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
St George's, University of London. "Drugs cut need for surgery for Crohn's disease sufferers by more than half." Medical News Today. MediLexicon, Intl., 29 Jan. 2014. Web.
19 Apr. 2014. <http://www.medicalnewstoday.com/releases/271847>
St George's, University of London. (2014, January 29). "Drugs cut need for surgery for Crohn's disease sufferers by more than half." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/271847.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT is the registered trade mark of MediLexicon International Limited.